title: Response to ranibizumab following tachyphylaxis to bevacizumab in a patient with radiation maculopathy following stereotactic fractionated radiotherapy for optic nerve meningioma.
authors.affiliation: Western Eye Hospital, Imperial College Healthcare NHS Trust, London, England.
authors.forename: Gurjeet
authors.initials: G
authors.lastname: Jutley
authors.forename: Olajumoke A
authors.initials: OA
authors.lastname: Shona
authors.forename: Richard Cheong
authors.initials: RC
authors.lastname: Leen
authors.forename: Nicholas
authors.initials: N
authors.lastname: Lee
authors.forename: Jane M
authors.initials: JM
authors.lastname: Olver
authors.forename: Sheena M
authors.initials: SM
authors.lastname: George
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use*; D000068258:Bevacizumab; D005500:Follow-Up Studies; D006801:Humans; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008579:Meningioma / Q000601:surgery*; D019574:Optic Nerve Neoplasms / Q000601:surgery*; D011832:Radiation Injuries / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D016634:Radiosurgery / Q000009:adverse effects*; D000069579:Ranibizumab; D013618:Tachyphylaxis; D041623:Tomography, Optical Coherence
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab